Dysgerminoma of the ovary in a four-year-old girl with metastases clinically simulating wilms' tumor and adrenal neuroblastoma

Mandeville, Frederick B.; Sahyoun, Philip F.; Sutton, L. E.

doi:10.1016/s0022-3476(49)80201-0

Cited by 7 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, extra-abdominal lymph nodes such as para-aortic, [23,25,26], supraclavicular [11] and cervical lymph nodes [26][27][28] may be involved. Distant hematogenous metastases develop in the bones [29][30][31], lungs (15%) [24], liver [29,31], kidneys [29], adrenal glands [31], mammary glands [32], cranium, brain, dura mater and intra-axial [24,33,34], pancreas [29], heart and skin [32]. There are also a number of other uncommon distant sites that have been reported: eye, placenta, central airways (bronchus-trachea), bladder (17%), pleura (33%), spleen (20%), bowel (50%) [22,35], and neurologic involvement such as carcinomatous meningitis [24,33,34].…”

Section: Discussionmentioning

confidence: 99%

Uncommon Metastasis of Ovarian Dysgerminoma: A Case Report and Review of the Literature

et al. 2021

View full text Add to dashboard Cite

Ovarian malignant germ cell tumors (OMGCT) represent less than 10% of all ovarian tumors. Dysgerminoma is the most common malignant primitive germ cell tumor in young women, known for its curability and low propensity to invade and metastasize when diagnosed early. Herein, we report an unusual type of ovarian dysgerminoma (OD) metastasis with a brief review of the literature, lacking similar reported cases. To our knowledge, although there are several case reports of dysgerminoma metastases with variable anatomic location and presentation, vaginal metastasis has not been previously described. The local or systemic relapse together with local and distant metastasis is considered as an independent predictor of poor survival in patients with OD. In light of the absence of mutations status, our patient successfully responded to therapy. Currently, the patient remains in clinical remission. A specific follow-up plan is ongoing knowing that ovarian dysgerminomas tend to recur most often in the first 2–3 years after treatment.

show abstract